You searched for Fibrodysplasia ossificans progressiva (FOP)

- 19 Décembre 2025

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia os...

- 16 Avril 2025

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full...

- 13 Février 2025

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

PARIS, FRANCE, 13 February 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024....

- 29 Juin 2023

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

PARIS, FRANCE, 29 June 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted in favor of investigational palovarotene as an effect...

- 16 Août 2023

US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossific...

- 12 Février 2026

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

PARIS, FRANCE, 12 February 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year (FY) 2025 and for the fourth quarter of 2025....

- 24 Août 2023

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Paris and Montréal, 25 February 2019 – Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage ...

- 26 Mai 2023

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

PARIS, FRANCE, 26 May 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the re-examination of palovarotene as a potential treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva, by the Committee for Medicinal Product...

- 26 Mai 2023

Ipsen reçoit un avis négatif du Comité des médicaments à usage humain (CHMP) à la suite du réexamen du palovarotène en tant que premier traitement de FOP au sein de l’Union européenne (UE)

PARIS, FRANCE, le 26 mai 2023 – Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd'hui que, malgré le réexamen du palovarotène pour le traitement potentiel de la FOP, une maladie osseuse ultra-rare, le CHMP de l'Agence eu...

- 19 Juillet 2023

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

PARIS, FRANCE, 19 July 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has followed guidance provided by the Committee for Medicinal Products for Human Use (CHMP) in May this year, and has not granted marketing autho...

Say	Action
“Show menu”	Open the accessibility menu
“Close menu”	Close the accessibility menu
“Disable voice navigation”	Stops voice command mode
“List Headings”	Provides a quick overview of all headings
“List landmarks”	Displays the main structural regions of a webpage
“List links”	Displays all hyperlinks on the page
“Tab next”	Moves focus to the next interactive element
“Tab back”	Moves focus to the previous interactive element
“Follow/click”	Activates the currently focused link or button
“Reload page”	Refreshes the current webpage
“Home page”	Returns the user to the home page
“Previous page”	Navigates back to the previously visited page
“Zoom in”	Increases the zoom level
“Zoom out”	Decreases the zoom level
“Move left”	Shifts the cursor to the left
“Move right”	Shifts the cursor to the right
“Move up”	Moves the cursor upward
“Move down”	Moves the cursor downward
“Move to beginning”	Moves the cursor to the beginning of the text
“Move to end”	Moves the cursor to the end of the text
“Select all”	Selects all text in the focused field, or all page text when no field is focused
“Clear all selection”	Removes the current highlight without deleting text. It also works after “Select all”.
“Type [text]”	Inserts [text] into the focused field. Say “space”, “blank space”, or “white space” between words, for example “Type hello space world”.
“Clear input”	Removes or resets text in the currently focused input field
“Cut”	Removes selected text and places it on the clipboard
“Copy”	Copies selected text to the clipboard without removing it
“Paste”	Reads clipboard text and inserts it into the focused editable field
“Lowercase”	Converts the selected text to lowercase.
”Uppercase”	Converts the selected text to uppercase
“Delete selected text”	Removes the currently highlighted or selected text
“Skip to main content”	Moves focus to the main content region
“Skip to navigation”	Allows users to quickly move to the main navigation menu
“Skip to footer”	Allows users to jump directly to the footer section of the webpage
“Show number on link”	Displays numbered labels for links on the page to simplify voice-based navigation
“Remove number from link”	Removes every visible voice number label from links. Use this after “Show numbers on links”.
“Go to [number]”	Moves focus to the link with that displayed number without opening it. First say “Show numbers on links”.
“Click [number]”	Opens the link with that displayed number. First say “Show numbers on links”, then say “Click 1”, “Click number 2”, or another displayed number.

Résultats de recherche